Roche Reports Phase 2 Data for Loncastuximab tesirine in Autoimmune hepatitis

Roche today announced Phase 2 results for Loncastuximab tesirine in patients with Autoimmune hepatitis. The study demonstrated that Loncastuximab tesirine demonstrates favorable safety profile compared to standard of care or placebo. These results provide important insights into the treatment of Autoimmune hepatitis and support the continued development of Loncastuximab tesirine in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Loncastuximab tesirine was consistent with previous observations, with no new safety signals identified.